抄録
We experienced a 78-year-old woman who was diagnosed with hereditary transthyretin cardiac amyloidosis and administered patisiran for advanced heart failure refractory to tafamidis. The levels of N-terminal pro B-type natriuretic peptide and left ventricular mass index decreased following the six-month patisiran treatment without any complications. Patisiran might be a promising disease-modifying drug for hereditary transthyretin cardiac amyloidosis even in its advanced stage, although further evaluation in a large cohort is warranted.
本文言語 | 英語 |
---|---|
ページ(範囲) | 177-180 |
ページ数 | 4 |
ジャーナル | Journal of Cardiology Cases |
巻 | 23 |
号 | 4 |
DOI | |
出版ステータス | 出版済み - 2021/04 |
ASJC Scopus 主題領域
- 循環器および心血管医学